Efficacy of Phentolamine in Prevention of Contrast-Associated Acute Kidney Injury After Complex PCI

Summary

To evaluate the efficacy and safety of phentolamine in prevention of CA-AKI following complex PCI in patients at high risk of CA-AKI.

Eligibility

Inclusion Criteria:

* Patients admitted to CCU with CAD.
* Patients underwent successful complex PCI defined as multivessel disease, more than two lesions, high coronary lesion complexity, chronic total occlusion, lesion length \>30 mm, or bifurcation.
* Patients at high or very high risk for CA-AKI based on Mehran-2 CA-AKI Risk Score (Model 2).

Exclusion Criteria:

* Patients with end stage renal disease on regular dialysis.
* Patients with failed PCI revascularization.
* Patients presented with STEMI and underwent primary PCI.
* Patients presented with high risk NSTEMI defined as elevated cardiac enzymes with chest pain refractory to medications and/or dynamic ST changes.
* Patients presented with cardiogenic shock.
* Patients presented with any degree of heart block.
* Patients with of history of asthma or hypersensitive for phentolamine.
* Patients on α-blockers, barbiturates or antipsychotic treatment.
* Patients intolerant to phentolamin with significant hemodynamic changes defined as \>20% drop of systolic blood pressure (SBP) or \>20% increase of heart rate (HR) after loading dose of phentolamine.

Conditions5

Browse More Trials